A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years
Phase of Trial: Phase IV
Latest Information Update: 05 Jun 2017
At a glance
- Drugs Perampanel (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- Sponsors Eisai Inc
- 23 Aug 2014 Status changed from not yet recruiting to recruiting as reported by United Kingdom Clinical Research Network
- 31 Mar 2014 Planned End Date changed from 1 Apr 2017 to 1 Jun 2017 according to ClinicalTrials.gov record.
- 31 Mar 2014 Planned initiation date changed from 1 Feb 2014 to 1 Apr 2014 according to ClinicalTrials.gov record.